This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
A Anand , DS Charney , DA Oren , RM Berman , XS Hu , A Cappiello , JH Krystal (2000). Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Archives of General Psychiatry 57, 270–276.
RM Berman , A Cappiello , A Anand , DA Oren , GR Heninger , DS Charney , JH Krystal (2000). Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 47, 351–354.
MD Black (2005). Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology (Berlin) 179, 154–163.
JD Bremner , JH Krystal , FW Putnam , SM Southwick , C Marmar , DS Charney , CM Mazure (1998). Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). Journal of Traumatic Stress 11, 125–136.
S Chourbaji , MA Vogt , F Fumagalli , R Sohr , A Frasca , C Brandwein , H Hörtnagl , MA Riva , R Sprengel , P Gass (2008). AMPA receptor subunit 1 (GluR-A) knockout mice model the glutamate hypothesis of depression. Journal of the Federation of American Societies for Experimental Biology 22, 3129–3134.
SP Cohen , MH Verdolin , AS Chang , C Kurihara , BJ Morlando , J Mao (2006). The intravenous ketamine test predicts subsequent response to an oral dextromethorphan treatment regimen in fibromyalgia patients. Journal of Pain 7, 391–398.
JFW Deakin , J Lees , S McKie , JEC Hallak , SR Williams , SM Dursun (2008). Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Archives of General Psychiatry 65, 154–164.
J Du , K Suzuki , Y Wei , Y Wang , R Blumenthal , Z Chen , C Falke , CA Zarate Jr., HK Manji (2007). The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 32, 793–802.
MF Egan , M Kojima , JH Callicott , TE Goldberg , BS Kolachana , A Bertolino , E Zaitsev , B Gold , D Goldman , M Dena , B Lu , DR Weinberger (2003). The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112, 257–269.
E Fumagalli , P Bigini , S Barbera , M De Paola , T Mennini (2006). Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease. Experimental Neurology 198, 114–128.
LS Garcia , CM Comim , SS Valvassori , GZ Reus , LM Barbosa , AC Andreazza , L Stertz , GR Fries , EC Gavioli , F Kapczinski , J Quevedo (2008). Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Progress in Neuropsychopharmacology and Biological Psychiatry 32, 140–144.
JR Geddes , SM Carney , C Davies , TA Furukawa , DJ Kupfer , E Frank , GM Goodwin (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361, 653–661.
MJ Hamilton , AF Cohen , AW Yuen , N Harkin , G Land , BC Weatherley , AW Peck (1993). Carbamazepine and lamotrigine in healthy volunteers: relevance to early tolerance and clinical trial dosage. Epilepsia 34, 166–173.
GD Honey , PR Corlett , AR Absalom , M Lee , E Pomarol-Clotet , GK Murray , PJ McKenna , ET Bullmore , DK Menon , PC Fletcher (2008). Individual differences in psychotic effects of ketamine are predicted by brain function measured under placebo. Journal of Neuroscience 28, 6295–6303.
DC Javitt (2004). Glutamate as a therapeutic target in psychiatric disorders. Molecular Psychiatry 9, 984–997.
LV Kalia , SK Kalia , MW Salter (2008). NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurology 7, 742–755.
CH Kellner , RG Knapp , G Petrides , TA Rummans , MM Husain , K Rasmussen , M Mueller , HJ Bernstein , K O'Connor , G Smith , (2006). Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Archives of General Psychiatry 63, 1337–1344.
A Khan , N Redding , WA Brown (2008). The persistence of the placebo response in antidepressant clinical trials. Journal of Psychiatric Research 42, 791–796.
RJ Knapp , R Goldenberg , C Shuck , A Cecil , J Watkins , C Miller , G Crites , E Malatynska (2002). Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. European Journal of Pharmacology 440, 27–35.
JH Krystal , EB Perry , R Gueorguieva , A Belger , SH Madonick , A Abi-Dargham , TB Cooper , L MacDougall , W Abi-Saab , DC D'Souza (2005). Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Archives of General Psychiatry 62, 985–995.
JH Krystal , IL Petrakis , E Webb , NL Cooney , LP Karper , S Namanworth , P Stetson , LA Trevisan , DS Charney (1998). Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Archives of General Psychiatry 55, 354–360.
AC Lahti , B Koffel , D LaPorte , CA Tamminga (1995). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13, 9–19.
WR Lenderking , M Hu , H Tennen , JC Cappelleri , CD Petrie , AJ Rush (2008). Daily process methodology for measuring earlier antidepressant response. Contemporary Clinical Trials. Published online: 17 June 2008. doi:10.1016/j.cct.2008.05.012.
X Li , JP Tizzano , K Griffey , M Clay , T Lindstrom , P Skolnick (2001). Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 40, 1028–1033.
S Maeng , CA Zarate (2008). The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Current Psychiatry Reports 9, 467–474.
S Maeng , CA Zarate Jr., J Du , RJ Schoesser , J McCammon , G Chen , HK Manji (2008). Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biological Psychiatry 63, 349–352.
M Mantovani , R Pertile , JB Calixto , AR Santos , AL Rodrigues (2003). Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-d-aspartate receptors and the L-arginine-nitric oxide pathway. Neuroscience Letters 343, 1–4.
SJ Mathew , HK Manji , DS Charney (2008 b). Novel drugs and drug targets for severe mood disorders. Neuropsychopharmacology 33, 2080–2092.
SJ Mathew , RB Price , X Mao , ELP Smith , JD Coplan , DS Charney , DC Shungu (2008 a). Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biological Psychiatry 63, 891–898.
HS Mayberg , AM Lozano , V Voon , HE McNeely , D Seminowicz , C Hamani , JM Schwalb , SH Kennedy (2005). Deep brain stimulation for treatment-resistant depression. Neuron 45, 651–660.
RG Miller , JD Mitchell , M Lyon , DH Moore (2007). Riluzole for amyotrophoic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database of Systematic Reviews Issue 1. Art. No.: CD001447.
I Mizuta , M Ohta , K Ohta , M Nishimura , E Mizuta , S Kuno (2001). Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes. Neuroscience Letters 310, 117–120.
SA Montgomery , M Asberg (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382–389.
K Nakamura , Y Tanaka (2001). Antidepressant-like effects of aniracetam in aged rats and its mode of action. Psychopharmacology (Berlin) 158, 205–212.
JE Overall , DR Gorham (1962). The Brief Psychiatric Rating Scale. Psychological Report 10, 799–812.
IL Petrakis , D Limoncelli , R Gueorguieva , P Jatlow , NN Boutros , L Trevisan , J Gelernter , JH Krystal (2004). Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. American Journal of Psychiatry 161, 1776–1782.
C Pittenger , V Coric , M Banasr , M Bloch , JH Krystal , G Sanacora (2008). Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 22, 761–786.
KG Rasmussen , M Mueller , RG Knapp , MM Husain , TA Rummans , SM Sampson , K O'Connor , G Petrides , M Fink , CH Kellner (2007). Antidepressant medication treatment failure does not predict lower remission with ECT for major depressive disorder: a report from the consortium for research in electroconvulsive therapy. Journal of Clinical Psychiatry 68, 1701–1706.
AJ Rush , HC Kraemer , HA Sackeim , M Fava , MH Trivedi , E Frank , PT Ninan , ME Thase , AJ Gelenberg , DJ Kupfer , ; ACNP Task Force (2006 b). Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 31, 1841–1853.
AJ Rush , MH Trivedi , HM Ibrahim , TJ Carmody , B Arnow , DN Klein , JC Markowitz , PT Ninan , S Kornstein , R Manber , (2003). The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry 54, 573–583 [Erratum, p. 585].
AJ Rush , MH Trivedi , SR Wisniewski , AA Nierenberg , JW Stewart , D Warden , G Niederehe , ME Thase , PW Lavori , BD Lebowitz , (2006 a). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry 163, 1905–1917.
HA Sackeim , RF Haskett , BH Mulsant , ME Thase , JJ Mann , HM Pettinati , RM Greenberg , RR Crowe , TB Cooper , J Prudic (2001). Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. Journal of the American Medical Association 285, 1299–1307.
HA Sackeim , J Prudic , DP Devanand , P Decina , B Kerr , S Malitz (1990). The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. Journal of Clinical Psychopharmacology 10, 96–104.
G Sanacora , SF Kendell , Y Levin , AA Simen , LR Fenton , V Coric , JH Krystal (2007). Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biological Psychiatry 61, 822–825.
G Sanacora , CA Zarate , JH Krystal , HK Manji (2008). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery 7, 426–437.
AJ Stern , AA Savostyanova , A Goldman , AS Barnett , JWC van der Veen , JH Callicott , VS Mattay , DR Weinberger , S Marenco (2008). Impact of the brain-derived neurotrophic factor val66met polymorphism on levels of hippocampal N-acetyl-aspartate assessed by magnetic resonance spectroscopic imaging at 3 tesla. Biological Psychiatry 64, 856–862.
A Yilmaz , D Schulz , A Aksoy , R Canbeyli (2002). Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacology Biochemistry and Behavior 71, 341–344.
RC Young , MT Schreiber , VE Ziegler , DA Meyer (1978). A rating scale for mania: reliability, validity, and sensitivity. British Journal of Psychiatry 133, 429–435.
CA Zarate Jr., JL Payne , J Quiroz , J Sporn , KK Denicoff , D Luckenbaugh , DS Charney , HK Manji (2004). An open-label trial of riluzole in patients with treatment-resistant major depression. American Journal of Psychiatry 161, 171–174.
CA Zarate Jr., JA Quiroz , JB Singh , KD Denicoff , G De Jesus , DA Luckenbaugh , DS Charney , HK Manji (2005). An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biological Psychiatry 57, 430–432.
CA Zarate Jr., JB Singh , PJ Carlson , NE Brutsche , R Ameli , DA Luckenbaugh , DS Charney , HK Manji (2006). Robust, rapid and relatively sustained antidepressant effects with a single-dose of an NMDA antagonist in treatment-resistant major depression: a double-blind placebo controlled study. Archives of General Psychiatry 63, 856–863.